@Adityalch@AndrewHires No they won't and here's why: GLP-1s are innately cheap to produce. That's how you have compounding pharmacies able to bypass big pharma. the -mabs are not. They're complex and fragile. Which means those drugs won't be in the reach of most people.
@AmericaAeterna@Polymarket At this point, with their contributions to open source, the Chinese companies are more American than the American companies are.